enfortumab vedotin,pembrolizumab
merck,astellas,seagen
['bladder', 'ev103']
#esmo22 key #bladdercancer presentations-one potentially practice-changing study (ev103 cohort k) - many important studies laying the foundation for future advances in therapy and #precisiononcology #medtwitter 
GU Oncology Director, AdventHealth Cancer Institute, Orlando, FL; Editor @practiceupdate #bladdercancer, #ASCO #ESMO; Following/RT ? endorsement, Views mine